Biomotion Sciences. Ordinary Shares SLXN 深 滬
等待開盤 02-10 09:30:00 美东时间
1.752
+0.142
+8.82%
華盛通- 最 高1.80
- 今 開1.73
- 成交量 4.45万股
- 最 低 1.73
- 昨 收 1.61
- 總市值 547.79万
- 52周最高 26.70
- 市盈率 靜 --
- 換手率 1.42%
- 52周最低 1.51
- 委 比 -11.30%
- 總股本 312.66万
- 歷史最高 627.75
- 量 比 2.25
- 振 幅 4.35%
- 歷史最低 1.51
- 每 手 1
- 風險率 5.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Litchfield Hills Initiates Coverage On Silexion Therapeutics with Buy Rating, Announces Price Target of $6
Litchfield Hills analyst Theodore O'Neill initiates coverage on Silexion Therapeutics (NASDAQ:SLXN) with a Buy rating and announces Price Target of $6.
2025-12-15 22:45
Silexion Therapeutics Receives Written Scientific Advice From German Regulator Regarding Proposed Design Of Phase 2/3 Clinical Study For SIL204 For Locally Advanced Pancreatic Cancer
Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received
2025-12-02 21:04
Silexion Therapeutics Q3 EPS $(2.88) Beats $(3.40) Estimate
Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(2.88) per share which beat the analyst consensus estimate of $(3.40) by 15.29 percent. This is a 98.95 percent increase over losses of $(274.05) per
2025-11-12 22:04
Silexion Therapeutics Unveils Promising SIL204 Data
An announcement from Silexion Therapeutics ( ($SLXN) ) is now available. On Sep...
2025-09-30 21:24
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
Silexion Therapeutics Corp.'s SIL204 has shown high activity against multiple KRAS mutations across various cancer types, achieving inhibition rates of 83.5%-99.7%. It demonstrates first evidence in gastric cancer and expanded validation in colorectal cancer, targeting mutations like G12R (17% of pancreatic cancers) hard to inhibit. SIL204's broad mutation coverage and strong activity raise hopes for a comprehensive pan-KRAS therapeutic solution....
2025-09-30 12:40
Market-Moving News for September 11th
SLXN: 50% | Silexion Highlights Preclinical Data Of SIL204 Supporting Dual-Route Treatment Strategy With Phase 2/3 Trial On Track For 2026 VNCE: 242% | Vince Holding Q2 Adj. EPS $0.38 Beats $(0.10)
2025-09-11 19:26
Silexion's SIL204 Reaches All Major Sites Of Pancreatic Cancer Spread And Cuts Tumor Burden In Preclinical Study
Silexion Therapeutics Corp. (NASDAQ:SLXN), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical data demonstrating that
2025-09-11 19:01
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
Silexion Therapeutics announced successful preclinical data for SIL204, demonstrating effective distribution to liver, peritoneum, and lungs, with measurable tumor burden reductions. The study validates the systemic component of their dual-route administration strategy, targeting both primary tumors and metastatic disease. Silexion plans to initiate Phase 2/3 trials in H1 2026, following regulatory submissions in Q4 2025 and Q1 2026.
2025-09-11 11:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 80.7% to $1.35 during Tues...
2025-09-10 01:06
